ENTA
Enanta Pharmaceuticals Inc
12.60$
-2.8%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | -5.8% | -52.9% | +89.4% | +280.0% | -53.3% | +47.0% | -44.5% | +144.4% | -90.1% | -1,087.5% | – | – | – | – | |
| – | -9.8% | -65.5% | +28.5% | +59.3% | +81.5% | +159.9% | +28.7% | +17.8% | +29.4% | +11.8% | -8.5% | -10.8% | -20.2% | -1.5% | +117.9% | |
| – | -13.1% | +88.4% | +150.7% | +152.3% | +117.7% | +60.2% | +39.7% | +21.2% | +21.3% | +1.8% | +7.2% | +28.5% | +4.6% | -5.0% | -30.7% | |
| – | – | – | – | – | – | -65.4% | +111.1% | +63.1% | -37.8% | +156.7% | -26.7% | +40.6% | – | – | – | |
| – | – | – | +696.8% | -404.7% | – | – | +256.0% | -381.2% | – | +12.3% | -206.1% | – | +18.2% | -11.1% | +459.7% | |
| – | +1,102.7% | -43.4% | +140.5% | +69.6% | +127.2% | +102.8% | -47.1% | +19.0% | +81.7% | -73.3% | -48.1% | +183.3% | +326.3% | +98.1% | -28.1% | |
| – | -1,163.3% | +2.0% | +283.7% | – | -17,843.7% | -50.5% | -89.5% | +674.3% | +144.8% | – | +86.5% | +48.4% | -197.6% | – | -30.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | -98.1% | +141.0% | -59.6% | -119.7% | +769.3% | +138.5% | -64.2% | -64.4% | +130.1% | +205.7% | – | – | |
| – | – | – | – | – | +0.0% | +0.0% | +7.4% | +8.2% | +8.9% | – | – | – | – | – | – | |
| – | +325.0% | -2,773.5% | – | -98.0% | +118.2% | +6.5% | -62.4% | +333.5% | -41.6% | +249.0% | -65.7% | +550.4% | +889.0% | -113.9% | -3.6% | |
| – | – | -42.3% | -145.0% | – | -141.1% | – | – | -103.6% | – | – | -183.4% | – | – | -216.3% | – | |
| – | – | -5.1% | -55.1% | +90.6% | +288.2% | -58.2% | +61.4% | -47.7% | +151.5% | -91.5% | -1,353.7% | – | – | – | – |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.